Drugs / DTA-H19
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00711997 | Aug 2009 → Oct 2010 | pancreatic neoplasm | Anchiano Therapeutics Israel Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT00393809 | Jan 2006 → Nov 2007 | urinary bladder neoplasm | Hebrew University of Jerusalem | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00595088 | Jan 2008 → Jan 2013 | superficial urinary bladder carcinoma | Anchiano Therapeutics Israel Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTA-H19 | “DTA-H19, is a doubled stranded DNA plasmid that carries the gene for the diphtheria toxin A (DT-A) chain under the regulation of the H19 promoter sequence.” NCT00595088 ↗ |
| Known as | DTA-H19/PEI | “Study treatments will consist of an induction course of six weekly instillations of 20 mg of DTA-H19/PEI into the urinary bladder.” NCT00595088 ↗ |
| Action | Deplete | “The selective initiation of toxin expression results in selective tumor cell destruction via inhibition of protein synthesis in the tumor cell” NCT00711997 ↗ |
| Modality | Other / unclassified | “DTA-H19 is a DNA plasmid that contains H19 gene regulatory sequences” NCT00393809 ↗ |
| Route | Other | “DTA-H19 given as six intravesical infusions into the bladder” NCT00393809 ↗ |